GEA
NBIX icon

Glen Eagle Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Glen Eagle Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42
Closed -$5.9K – 1110
2025
Q3 		$5.9K Buy
+42
New +$5.69K ﹤0.01% 767
2020
Q4 		– Sell
-110
Closed -$10.6K – 1000
2020
Q3 		$10.6K Buy
+110
New +$12.7K ﹤0.01% 586
2020
Q1 		– Sell
-65
Closed -$6.99K – 906
2019
Q4 		$6.99K Buy
+65
New +$6.81K ﹤0.01% 660
2018
Q1 		– Sell
-55
Closed -$4.27K – 699
2017
Q4 		$4.27K Hold
55
– – ﹤0.01% 527
2017
Q3 		$3.37K Hold
55
– – ﹤0.01% 552
2017
Q2 		$2.53K Buy
+55
New +$2.67K ﹤0.01% 527

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Glen Eagle Advisors's NBIX Position: Q4 2025 in Review

Glen Eagle Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 42 shares — an estimated $5.9K sold.

Glen Eagle Advisors first reported a position in NBIX in Q2 2017 and held it in 6 quarters. The position peaked at $10.6K in Q3 2020. 730 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Glen Eagle Advisors reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Glen Eagle Advisors sold 42 Neurocrine Biosciences shares in Q4 2025, an estimated $5.9K.
  • Glen Eagle Advisors first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 6 quarters.
  • Glen Eagle Advisors's Neurocrine Biosciences position peaked at $10.6K in Q3 2020.
  • 730 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Glen Eagle Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.